Related Experiment Video

Updated: Jun 10, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Advances in targeting SRC in the treatment of breast cancer and other solid malignancies

Erica L Mayer1, Ian E Krop

  • 1Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. emayer@partners.org

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|July 17, 2010
PubMed

Insights

Src tyrosine kinase is implicated in cancer growth and migration. Inhibitors show promise in early trials, especially when combined with other cancer therapies like endocrine or angiogenesis treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Src is a nonreceptor tyrosine kinase crucial for cell signaling pathways.
  • Increased Src activity is linked to various human cancers, including breast and prostate cancer.
  • Src regulates critical cellular functions such as growth, survival, invasion, adhesion, and migration.

Purpose of the Study:

  • To review the role of Src in malignancies.
  • To discuss the therapeutic potential of Src inhibitors in cancer treatment.
  • To explore ongoing and future clinical trials investigating Src inhibitor combinations.

Main Methods:

  • Preclinical studies evaluating Src inhibitors.
  • Analysis of early-phase clinical trials (e.g., dasatinib, bosutinib).
  • Review of interactions between Src and other signaling pathways (estrogen receptor, VEGFR).

Main Results:

  • Src inhibitors demonstrate antitumor effects in preclinical models.
  • Early trials suggest modest efficacy of Src inhibitors as monotherapy in breast and prostate cancer.
  • Potential for enhanced activity when Src inhibitors are used in combination regimens.

Conclusions:

  • Src inhibitors represent a promising therapeutic strategy for various solid tumors.
  • Combination therapies involving Src inhibitors with endocrine agents, angiogenesis inhibitors, chemotherapy, and targeted agents warrant further investigation.
  • Targeting Src signaling offers a viable approach to combatting human malignancies.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...